Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;64(3):358-67.
doi: 10.1002/acr.20684.

Validation of potential classification criteria for systemic sclerosis

Affiliations

Validation of potential classification criteria for systemic sclerosis

Sindhu R Johnson et al. Arthritis Care Res (Hoboken). 2012 Mar.

Abstract

Objective: Classification criteria for systemic sclerosis (SSc; scleroderma) are being updated jointly by the American College of Rheumatology and European League Against Rheumatism. Potential items for classification were reduced to 23 using Delphi and nominal group techniques. We evaluated the face, discriminant, and construct validity of the items to be further studied as potential criteria.

Methods: Face validity was evaluated using the frequency of items in patients sampled from the Canadian Scleroderma Research Group, 1000 Faces of Lupus, and the Pittsburgh, Toronto, Madrid, and Berlin connective tissue disease (CTD) databases. Patients with SSc (n = 783) were compared to 1,071 patients with diseases similar to SSc (mimickers): systemic lupus erythematosus (n = 499), myositis (n = 171), Sjögren's syndrome (n = 95), Raynaud's phenomenon (RP; n = 228), mixed CTD (n = 29), and idiopathic pulmonary arterial hypertension (PAH; n = 49). Discriminant validity was evaluated using odds ratios (ORs). For construct validity, empirical ranking was compared to expert ranking.

Results: Compared to mimickers, patients with SSc were more likely to have skin thickening (OR 427); telangiectasias (OR 91); anti-RNA polymerase III antibody (OR 75); puffy fingers (OR 35); finger flexion contractures (OR 29); tendon/bursal friction rubs (OR 27); anti-topoisomerase I antibody (OR 25); RP (OR 24); fingertip ulcers/pitting scars (OR 19); anticentromere antibody (OR 14); abnormal nailfold capillaries (OR 10); gastroesophageal reflux disease symptoms (OR 8); antinuclear antibody, calcinosis, dysphagia, and esophageal dilation (all OR 6); interstitial lung disease/pulmonary fibrosis (OR 5); and anti-PM-Scl antibody (OR 2). Reduced carbon monoxide diffusing capacity, PAH, and reduced forced vital capacity had ORs of <2. Renal crisis and digital pulp loss/acroosteolysis did not occur in SSc mimickers (OR not estimated). Empirical and expert ranking were correlated (Spearman's ρ = 0.53, P = 0.01).

Conclusion: The candidate items have good face, discriminant, and construct validity. Further item reduction will be evaluated in prospective SSc and mimicker cases.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURES

Sindhu R. Johnson has no financial or other conflicts of interest in relation to this manuscript.

Jaap Fransen has no financial or other conflicts of interest in relation to this manuscript.

Dinesh Khanna has no financial or other conflicts of interest in relation to this manuscript.

Murray Baron has no financial or other conflicts of interest in relation to this manuscript.

Frank van den Hoogen has no financial or other conflicts of interest in relation to this manuscript.

Thomas A. Medsger Jr. has no financial or other conflicts of interest in relation to this manuscript.

Christine A. Peschken has no financial or other conflicts of interest in relation to this manuscript.

Patricia E. Carreira has no financial or other conflicts of interest in relation to this manuscript.

Gabriela Riemekasten has no financial or other conflicts of interest in relation to this manuscript.

Alan Tyndall has no financial or other conflicts of interest in relation to this manuscript.

Marco Matucci-Cerinic has no financial or other conflicts of interest in relation to this manuscript.

Janet E. Pope has no financial or other conflicts of interest in relation to this manuscript.

Figures

Figure 1
Figure 1
Scatter plot of the empiric-based ranking and the expert-based ranking of the candidate items. The correlation between the 2 rankings was Spearman rho 0.53, p=0.01.

Similar articles

Cited by

References

    1. Masi AT, Medsger TA, Jr, Rodnan GP, Fries JF, Altman RD, Brown BW, et al. Methods and Preliminary Results of the Scleroderma Criteria Cooperative Study of the American Rheumatology Association. ClinRheumDis. 1979;5(1):27–48.
    1. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980 May;23(5):581–590. - PubMed
    1. Preliminary criteria for the classification of systemic sclerosis (scleroderma) BullRheumDis. 1981;31(1):1–6. - PubMed
    1. Nadashkevich O, Davis P, Fritzler MJ. A proposal of criteria for the classification of systemic sclerosis. MedSciMonit. 2004;10(11):CR615–CR621. - PubMed
    1. Walker JG, Pope J, Baron M, Leclercq S, Hudson M, Taillefer S, et al. The development of systemic sclerosis classification criteria. Clin Rheumatol. 2007 Sep;26(9):1401–1409. - PubMed

Publication types

MeSH terms